26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
07 December 2022 - Destiny Pharma plcDestiny Pharma announces finalisation of its Phase 3 development plans for XF-73 NasalThere is a significant, billion-dollar, potential global commercial opportunity for XF-73 Nasal gel to help prevent hospital infections and to…read more >>
28 November 2022 - Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisThe Phase 1 trial is an open-label, randomized, single-dose, crossover study to assess the safety and pharmacokinetics of oral (600…read more >>
15 November 2022 - Destiny Pharma plcDestiny Pharma: XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAIDXF-73 is the lead drug candidate from Destiny Pharma's XF platform, initially being developed for the prevention of post-surgical staphylococcal…read more >>
24 October 2022 - BasileaBasilea: ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the treatment of Staphylococcus aureus bacteremia (SAB)Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity…read more >>
17 October 2022 - GARDP FoundationGermany and other funders pledge support to GARDP to ramp up efforts in countering antibiotic resistanceThe Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization based in Switzerland developing new treatments for drug-resistant…read more >>
13 October 2022 - Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022The oral presentation, entitled “Ri-CoDIFy - A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole…read more >>
17 March 2025BIO-Europe Spring® 2025 – 19th Annual International Partnering ConferenceBIO-Europe Spring will bring together over 3,700 leading executives from around the world. Specifically, we will host more than 20,000…read more >>
25 February 20259th AMR ConferenceSave the date! The 9th AMR Conference will be organized as a face-to-face event on 25-26 February 2025, in Basel.…read more >>
03 December 2024REVIVE Webinar: Implementation research for the appropriate use of, and access to, antimicrobialsThis webinar will explore how implementation research has successfully led to the updating of guidelines for other drugs and discuss…read more >>
04 November 2024BIO-Europe ® 2024 – 30th Annual International Partnering ConferenceOver the last 30 years, BIO-Europe, has become Europe’s flagship partnering event. Its international reach makes it a one-of-a-kind offering,…read more >>
19 September 2024REVIVE Webinar: An introduction to antibiotic research and development (R&D)Itroduction to the stages from discovery to the phases of clinical trials and pharmaceutical development - A must-watch for clinicians…read more >>
22 August 2024REVIVE Webinar: Exploring non-traditional antimicrobials: Insights from three casesFind out the latest in the development of non-traditional antimicrobials from Jennifer Schneider at Centauri Therapeutics, Rida Mourtada at Lytica…read more >>
23 July 2024REVIVE Webinar: The value of surveillance data in defining the medical need for new antimicrobialsIn this webinar, the speakers will show the value of susceptibility surveillance data in defining the need for new antibacterials,…read more >>
27 June 2024REVIVE Webinar: Progressing an antibacterial drug discovery project – an SME perspectiveAlisa Serio from Paratek Pharma and Victoria Savage from INFEX Therapeutics will focus on the particular challenges, progression criteria and…read more >>
23 April 2024REVIVE Webinar: Efflux inhibitors: A strategy to tackle multidrug resistanceThe next REVIVE webinar will feature an overview of bacterial efflux and how molecules designed to inhibit this can be…read more >>
